Ignite Creation Date:
2024-07-17 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06475417
Status:
RECRUITING
Last Update Posted:
2024-06-26
First Post:
2024-05-28
Brief Title:
Neoadjuvant Adebrelimab DOS in Locally Advanced Resectable Gastric Cancer
Sponsor:
Tang-Du Hospital
Organization:
Tang-Du Hospital
Study Overview
Official Title:
Phase II Study of Neoadjuvant Adebrelimab Docetaxel Oxaliplatin and S-1 in Patients With Resectable Advanced Gastric Cancer
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy and safety of adebrelimab combined DOS in neoadjuvant treatment of locally advanced resectable gastric cancer
Detailed Description:
This prospective single-center single-arm clinical trial aims to enroll 42 treatment-naïve patients diagnosed with locally advanced gastric adenocarcinoma who are deemed operable Following informed consent patients will undergo screening to confirm eligibility Subsequently eligible participants will receive the standard dosage of Adebrelimab in combination with the DOS regimen for three cycles as neoadjuvant therapy prior to surgery Within 3-6 weeks after completing the third cycle preoperative imaging will be conducted to assess the efficacy of the novel neoadjuvant treatment and feasibility of achieving radical D2 resection Patients will then undergo radical surgical resection for gastric cancer with pathological complete response pCR being observed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None